PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise
NORCROSS, Ga. , May 28, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced its Rights Offering has closed.  The Rights Offering resulted in the issuance of approximately 10.4 million shares of the
View HTML
Toggle Summary Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering
NORCROSS, Ga. , May 23, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price (i.e., the final computed price) of the common stock and related warrant subscribed in its Rights
View HTML
Toggle Summary Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders Dated May 10, 2019
NORCROSS, Ga. , May 10, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein .  The letter reads as follows: Dear Fellow
View HTML
Toggle Summary Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update
Subscription rights to purchase Galectin Therapeutics, Inc. common shares, with accompanying warrants, mailed to Holders of Record as of April 29.  Rights expire at 5:00 PM Eastern on May 23, 2019 Portion of the Net Proceeds of Rights Offering to be used for Phase 3 clinical trial of belapectin,
View HTML
Toggle Summary Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
NORCROSS, Ga. , April 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has set key dates and pricing structure for its previously announced rights offering of approximately 14 million
View HTML
Toggle Summary Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
NORCROSS, Ga. , April 02, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin , the Company’s President and Chief Executive Officer, will present at the H.C.
View HTML
Toggle Summary Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
NORCROSS, Ga. , March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins, announced today a presentation highlighting the improved response of T cells seen in combination
View HTML
Toggle Summary Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein .  The letter reads as follows: Dear
View HTML
Toggle Summary Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
Richard E. Uihlein, Board Chair, expresses interest in investing $20.0 million in the Rights Offering NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration
View HTML
Toggle Summary Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
View HTML